Toremifene
- Generic Name
- Toremifene
- Brand Names
- Fareston
- Drug Type
- Small Molecule
- Chemical Formula
- C26H28ClNO
- CAS Number
- 89778-26-7
- Unique Ingredient Identifier
- 7NFE54O27T
- Background
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like tamoxifen, toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs.
Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
- Indication
For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.
- Associated Conditions
- Metastatic Breast Cancer
- Associated Therapies
- -
Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- Joel Nelson, MD
- Target Recruit Count
- 45
- Registration Number
- NCT00020735
- Locations
- 🇺🇸
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
- Conditions
- Breast NeoplasmsNeoplasms, Hormone-dependent
- Interventions
- Drug: atamestaneDrug: letrozoleDrug: aromatase inhibitionDrug: toremifeneProcedure: hormone therapyProcedure: endocrine therapyProcedure: antiestrogen therapy
- First Posted Date
- 2002-08-27
- Last Posted Date
- 2015-07-31
- Lead Sponsor
- Intarcia Therapeutics
- Target Recruit Count
- 865
- Registration Number
- NCT00044291
- Locations
- 🇺🇦
Kharkov Medical Academy of Postgraduate Education, Oncology and Pediatric Oncology Department. Clinical Facility: Kharkov Regional Clinical Oncology Dispensary, Chemotherapy Department, Kharkov, Ukraine
🇺🇦Odessa State Medical University, Oncology Department. Clinical Facility: Odessa Regional Oncology Center, Chemotherapy Department, Odessa, Ukraine
🇷🇺V. Novgorod Regional Oncology Center, Department of Chemotherapy, V. Novgorod, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.